Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxium plus ranibizumab to reduce injection frequency in diabetic macular edema
ChiCTR2100043531Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- Mar 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of calcium dobesilate and ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by First Affiliated Hospital of Jinan University. Primary endpoint: Anti-VEGF frequency. Started Mar 2021; status: recruiting.
02
Drugs
calcium dobesilateranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2100043531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043531.